VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML

NCT07407140 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

AML, Adult

Interventions

DRUG: Gilteritinib + Azacitidine + Venetoclax
DRUG: Cytarabine + Daunorubicin (or Idarubicin) + Gilteritinib
DRUG: Re-induction Therapy
DRUG: Consolidation Therapy
DRUG: Maintenance Therapy

Sponsor

Institute of Hematology & Blood Diseases Hospital, China